HK Stock Market Move | Some innovative pharmaceutical concept stocks have risen. The National Healthcare Security Administration stated that more innovative drugs are expected to be included in medical insurance reimbursement. A national healthcare discussion is about to be held.

Several innovative pharmaceutical stocks have risen, as of press time, AKESO (09926) is up 11.67%, priced at HKD 101.4; InnoCare Pharma (09969) is up 4.6%, priced at HKD 15.45; HUTCHMED (00013) is up 3.11%, priced at HKD 22.56; BeOne Medicines Ltd. (06160) is up 1.92%, priced at HKD 222.4. In terms of news, Li Tao, Deputy Director of the National Healthcare Security Administration, stated on September 4 during a series of themed press conferences on the start of the 14th Five-Year Plan held by the State Council Information Office, that there will be continued annual adjustments to the basic medical insurance drug catalog, incorporating more eligible innovative drugs for major diseases, key areas including tumors, chronic diseases, rare diseases, and pediatric conditions into the reimbursement scope of medical insurance. He emphasized efforts to promote a national unification of the medical service project and medical consumables reimbursement catalog, further narrowing policy differences between regions. It is noteworthy that, according to the Securities Times, negotiations for pricing the national basic medical insurance drug catalog and commercial insurance innovative drug catalog will be launched on September 5 at the National People's Congress conference center. Preliminary communications between the National Healthcare Security Administration and negotiating companies were completed last week. This year, pricing negotiations for the commercial insurance innovative drug catalog will also take place, aiming to formulate a new version of the commercial insurance innovative drug catalog.